The Wilms' tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis.
The Wilms' tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis.
复制标题
DOI：
10.18632/oncotarget.23671
复制
发表时间：
2018-03-23
期刊：
影响因子：
--
通讯作者：
Zhao Z
中科院分区：
文献类型：
--
作者：
Jiang Y;Liu L;Wang J;Cao Z;Zhao Z
以往的研究表明，Wilms肿瘤基因-1（WT 1）可能与骨髓增生异常综合征（MDS）患者的无复发生存期（RFS）和总生存期（OS）降低有关。因此，我们对WT 1作为MDS预后指标的效用进行了荟萃分析。在以下数据库中检索已发表的报告：科克伦图书馆、PubMed、Embase和Web of Science。使用科克伦协作RevMan 5.2软件进行荟萃分析。6篇文献（共450例患者）符合入选标准，并接受了进一步检查。结果显示，随着WT 1表达水平的增加，总生存期（OS）和无白血病生存期（LFS）均降低：（比值比，OR = 0.16; 95%CI = 0.08-0.34，P < 0.001），3年OS（OR = 0.21; 95%CI = 0.09-0.47，P < 0.001），5年OS（OR = 0.24; 95% CI = 0.06-0.92，P = 0.04），1年LFS（OR = 0.06; 95% CI = 0.02-0.18; P < 0.001）、3年LFS（OR = 0.20; 95% CI = 0.09-0.46; P < 0.001）和5年LFS（OR = 0.12; 95% CI = 0.04-0.38; P < 0.001）。就接受造血干细胞移植的患者而言，WT 1过表达组的累积复发率（CIR）高于低表达组：1年CIR（OR = 13.69; 95% CI = 2.99-62.62; P < 0.001），3年CIR（OR = 6.52; 95% CI = 2.31-18.40，P < 0.001）。总之，WT 1过表达是MDS的预后因素。
Previous studies have suggested that Wilms’ tumor gene-1 (WT1) may be related to a decrease in both relapse-free survival (RFS) and overall survival (OS) for patients with myelodysplastic syndrome (MDS). Therefore, we conducted a meta-analysis on the utility of WT1 as a prognostic indicator of MDS. Published reports were searched in the following databases: Cochrane Library, PubMed, Embase, and Web of Science. The meta-analysis was conducted using the Cochrane Collaboration RevMan 5.2 software. Six publications with 450 total patients met the inclusion criteria and were subjected to further examination. The results showed a reduction in both overall survival (OS) and leukemia-free survival (LFS) with increasing WT1 expression levels: 1-year OS (odds ratio, OR = 0.16; 95% CI = 0.08–0.34, P < 0.001), 3-year OS (OR = 0.21; 95% CI = 0.09–0.47, P < 0.001), 5-year OS (OR = 0.24; 95% CI = 0.06–0.92, P = 0.04), 1-year LFS (OR = 0.06; 95% CI = 0.02–0.18; P < 0.001), 3-year LFS (OR = 0.20; 95% CI = 0.09–0.46; P < 0.001), and 5-year LFS (OR = 0.12; 95% CI = 0.04–0.38; P < 0.001). In terms of patients receiving hematopoietic stem cell transplantation, the cumulative incidence of relapse (CIR) was higher in the WT1 over-expression group than in the low-expression group: 1-year CIR (OR = 13.69; 95% CI = 2.99–62.62; P < 0.001), 3-year CIR (OR = 6.52; 95% CI = 2.31–18.40, P < 0.001). In conclusion, WT1 over-expression is a prognostic factor for MDS.